UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure Biotech Inc. The collaboration aims to accelerate the market penetration and commercialization of QuantuMDx’s Q-POC platform and related assays in China. Q-POC is a rapid, portable multiplex PCR device designed for real-world healthcare settings and multiple indications.
Partnership Details
Under the agreement, Sansure gains exclusive rights to Q-POC in China in exchange for undisclosed licensing and royalty payments. Sansure will participate in developing assays for the platform, while QuantuMDx retains exclusive rights to sell those assays outside China. This partnership is expected to lead to lower-cost products tailored to the Chinese market.
Investment and Product Background
Previously, Hong Kong-based VC fund Vita Spring IVD Fund L.P. invested GBP 15 million (USD 17.5 million) in QuantuMDx in November 2021. Q-POC has received European CE marks for two assays: one for the SARS-CoV-2 virus and a multi-target array for respiratory diseases covering SARS-CoV-2, influenza A/B, and RSV.-Fineline Info & Tech
